La cadena de opciones muestra datos clave de las opciones de acciones de Reviva Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Reviva Pharmaceuticals..

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

REVIVA PHARMACEUTICALS HOLDI

Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings, Inc. - Warrants

Barclays analyst Benjamin Theurer maintains Ambev (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABEV#NYSE">ABEV</a>) with a Equal-Weight and raises the price target from $2 to $2.5.

News

Price Target

Analyst Ratings

ABEV

Barclays Maintains Equal-Weight on Ambev, Raises Price Target to $2.5

WIIM

RSLS

ReShape Lifesciences shares are trading lower after the company announced it filed for a mixed shelf offering of up to $50 million.

Barclays analyst Ramsey El-Assal maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Overweight and raises the price target from $45 to $53.

AFRM

Barclays Maintains Overweight on Affirm Holdings, Raises Price Target to $53

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) price target from $55 to $45. Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating. Intellia Therapeutics shares closed at $8.12 on Friday. <a href="https://www.benzinga.com/quote/NTLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) from $12 to $14. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Nexxen International shares closed at $11.54 on Friday. <a href="https://www.benzinga.com/quote/NEXN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) price target from $35 to $28. Goldman Sachs analyst Stephen Laszczyk downgraded the stock from Buy to Neutral. Warner Music shares closed at $27.36 on Friday. See how other analysts <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co slashed the price target for Ocugen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) from $8 to $7. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintained a Buy rating. Ocugen shares closed at $0.67 on Friday. <a href="https://www.benzinga.com/quote/OCGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham slashed the price target for Vir Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) from $19 to $14. Needham analyst Joseph Stringer maintained a Buy rating. Vir Biotechnology shares closed at $5.09 on Friday. <a href="https://www.benzinga.com/quote/VIR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan raised Teva Pharmaceutical Industries Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NASDAQ">TEVA</a>) price target from $21 to $23. JP Morgan analyst Chris Schott upgraded the stock from Neutral to Overweight. Teva Pharmaceutical shares settled at $16.93 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) price target from $226 to $303. Jefferies analyst David Katz upgraded the stock from Hold to Buy. Marriott shares closed at $257.97 on Friday. <a href="https://www.benzinga.com/quote/MAR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised DENTSPLY SIRONA Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) price target from $20 to $21. Barrington Research analyst Michael Petusky maintained an Outperform rating. Dentsply Sirona shares closed at $15.81 on Friday.  <a href="https://www.benzinga.com/quote/XRAY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt slashed the price target for TeraWulf Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) from $4.5 to $4. Rosenblatt analyst Chris Brendler maintained a Buy rating. TeraWulf shares settled at $3.01 on Friday. <a href="https://www.benzinga.com/quote/WULF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital raised Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) price target from $14 to $27. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. Medicus Pharma shares closed at $4.69 on Friday. <a href="https://www.benzinga.com/quote/MDCX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MAR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png" alt="" class="wp-image-911954" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/12094338/image-127.png 1130w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45342900/5-stock-picks-last-week-from-wall-streets-most-accurate-analysts-5">5 Stock Picks Last Week From Wall Street&#8217;s Most Accurate Analysts</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

MDCX

NEXN

NTLA

OCGN

TEVA

WULF

XRAY

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday

ALCY

Trading Halt: Halt status updated at 9:45:00 AM ET: Quotation Resumption: News and Resumption Times

Stephens &amp; Co. analyst Trey Grooms maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Equal-Weight and lowers the price target from $73 to $65.

TREX

Stephens & Co. Maintains Equal-Weight on Trex Co, Lowers Price Target to $65

DCGO

DocGo shares are trading lower after Canaccord Genuity downgraded the stock from Buy to Hold and lowered its price target from $5 to $1.45.

Barrington Research analyst Vincent Colicchio maintains Information Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) with a Outperform and raises the price target from $3.75 to $5.5.

Barrington Research Maintains Outperform on Information Services Gr, Raises Price Target to $5.5

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) is up another 4%, prompting trader to echo new predictions of a $1 price target backed by strong technical signals and <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">rising whale activity</a>.
What Happened: Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1921852362047766908">expects</a> DOGE to soon hit his diamond bottom target of $0.29, while macro investor Raoul Pal took to<a href="https://x.com/RaoulGMI/status/1921375109345866117"> X</a> on May 11 to muse about the idea of Dogecoin becoming the &#8220;hardest currency&#8221; in the world. 
He cited the DOGE/BTC chart, which he believes is forming a large bull flag, a pattern that typically precedes significant upward moves.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I still think the most amusing outcome possible would be for <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> to be the hardest currency on earth&#8230; this is the DOGE/BTC chart&#8230;to me it looks like a potential big flag pattern and new highs await&#8230; <a href="https://t.co/s7ZC43zhdf">pic.twitter.com/s7ZC43zhdf</a>
&mdash; Raoul Pal (@RaoulGMI) <a href="https://twitter.com/RaoulGMI/status/1921375109345866117?ref_src=twsrc%5Etfw">May 11, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, crypto analyst Kevin <a href="https://www.youtube.com/watch?v=FjPEq40aEHo">made</a> a compelling technical case for Dogecoin hitting $1 by year-end n his May 11 podcast. 
He points out that in previous bull cycles, Dogecoin&#8217;s monthly RSI reached at least 89.4, a level not yet hit in the current run. 
DOGE previously touched $0.50 when RSI was just 75, suggesting more room to run.
Kevin also referenced the Pi Cycle MA, a metric that accurately signaled DOGE tops in 2017 and early 2021. 
Currently, the indicator shows no signs of an imminent peak. He estimates DOGE needs to hit $0.40–$0.41 before it even starts flashing overbought conditions.
&#8220;First price target is going to be getting back to that 48-cent level, then it&#8217;ll be getting to previous all-time highs at 73-74 cents,&#8221; he advised, while cautioning against holding altcoins long-term regardless of price action.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45318242/dogecoin-surges-26-in-under-three-days">Dogecoin Surges 26% In 3 Days: What Is Going On?</a>
Why It Matters: Kevin added that a shift toward easing monetary policy, including rate cuts and the end of quantitative tightening, tends to benefit altcoins, especially as Bitcoin dominance starts to wane.
Adding to the momentum, crypto analyst Ali Martinez, in an X <a href="https://x.com/ali_charts/status/1921296433262846089">post</a> on May 11, reported that DOGE whales scooped up 600 million DOGE in just the past two days.
According to Coinglass, Dogecoin open interest surged 11.3% to $3.16 billion, the highest level since February. 
Liquidations in the past 24 hours reached $20 million, split between $10.6 million in shorts and the rest in longs, reflecting how rapidly sentiment and positioning are shifting.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45337617/dogecoin-rockets-up-27-while-bitcoin-climbs-toward-all-time-high">Dogecoin Rockets Up 27% While Bitcoin Climbs Toward All-Time High</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Dogecoin Jumps 4%: Can DOGE Hit $1 Soon?

Keybanc analyst Jason Celino maintains Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) with a Overweight and raises the price target from $270 to $285.

PAYC

Keybanc Maintains Overweight on Paycom Software, Raises Price Target to $285

BWS Financial analyst Hamed Khorsand maintains Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) with a Buy and maintains $440 price target.

BWS Financial Maintains Buy on Ubiquiti, Maintains $440 Price Target

Earnings

Earnings Beats

LINC

UPDATE: Lincoln Educational Servs Q1 Adj. EPS $0.11 Beats $0.04 Estimate,

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png" alt="" class="wp-image-12780" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/12074321/Zhipu-0512-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The company, which focuses on large language models for enterprise clients, has raised 2 billion yuan this year, from mostly government sources
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>Zhipu AI is aiming to become the first of China's "AI tigers" to go public, as its competitors pivot away from costly foundational model development</li>
<li>The company relies heavily on government support, but such a strategy also carries risks, as other AI leaders have learned</li>
</ul>
Recognition or general knowledge?
That's the question confronting China's bumper crop of AI startups these days, as they try to chart a path that keeps them clear of controversy and overreliance on state support while also providing strong growth potential. While many of the earliest players focused on recognition AI that has found one of its biggest applications in surveillance, a newer generation of startups is finding bigger potential – and less controversy – in knowledge-based large language models (LLMs) like those from OpenAI and, more recently, DeepSeek.
Now, one of those,&nbsp;Zhipu AI,&nbsp;is aiming to become the first among a new group of pure LLM companies to go public, taking its first step towards an IPO by filing documentation with the Beijing Securities Regulatory Bureau last month,&nbsp;<a href="https://www.caixin.com/2025-04-15/102309642.html">according to</a>&nbsp;financial media Caixin. If the process goes smoothly, Zhipu could become the first of China's six " AI tigers" raised on knowledge-based LLMs to tap the public capital markets.
The company is widely regarded as one of the most likely survivors among these six players in China's fiercely competitive AI landscape. Their space in LLMs has been recently disrupted by DeepSeek, which has gained significant attention following its recent release of more cost-effective models, including its reasoning-focused R1.
Despite its recent sudden leap to fame, DeepSeek isn't considered one of the six AI tigers in LLMs. Among the other five –&nbsp;MiniMax,&nbsp;Moonshot,&nbsp;Baichuan,&nbsp;StepFun&nbsp;and&nbsp;01.AI&nbsp;– two have already signaled a strategic shift away from foundational model development, of which LLMs are a subset. 01.AI, founded by AI pioneer and prominent venture capitalist and former Google China chief Lee Kai-Fu, has indicated it will cease investing in the development of foundational models, which demands substantial investment in AI chips and R&amp;D.
Instead, these companies are pivoting toward developing applications based on foundational models developed by other companies like DeepSeek. Baichuan, founded by Wang Xiaochuan, former CEO of search engine Sougou, has similarly indicated a strategic pivot, focusing on healthcare applications rather than continuing investment in foundational models.
While the other three companies haven't commented on their strategies lately, Zhipu AI stands out with its unequivocal commitment to foundational model development. The company has recently doubled down on this approach, launching a general-purpose AI agent in March, powered by its proprietary GLM model. It has also&nbsp;<a href="https://www.reuters.com/technology/artificial-intelligence/chinas-zhipu-ai-launches-free-ai-agent-intensifying-domestic-tech-race-2025-03-31/">taken the additional step</a>&nbsp;of open-sourcing its foundational models, similar to DeepSeek.
<h4 class="wp-block-heading">State backing</h4>
Among the foundational AI tigers, Zhipu has demonstrated a noteworthy ability to raise funds. While its peers have been quiet on that front over the past year, Zhipu has emerged as an investor favorite, securing at least 2 billion yuan ($276 million) in fresh funds this year alone.
The fundraising streak began in early March when the municipal government of Hangzhou, capital of Zhejiang province, emerged as the lead investor in a 1 billion yuan funding round. This was followed by investments from three other Chinese cities: Zhuhai in Guangdong province contributed 500 million yuan; Chengdu, capital of Sichuan province, invested 300 million yuan; and most recently, the Beijing municipal government provided 200 million yuan.
The recent funding wave is noteworthy for being led by government-backed sources, as China moves aggressively to develop the sector. Zhipu's seizing on that largess marks a shift for the company from its previous reliance on private capital.
Founded in 2019 by Tsinghua University alumni Tang Jie and Zhang Peng, Zhipu AI began within the university's walls and was later spun off. Its early funding rounds attracted prominent private investors like HongShan – formerly Sequoia China – and Chinese internet giants such as Alibaba and Tencent. Its roots at China's most famous sciences university may be at least partly behind the recent flood of state capital to the company.
Zhipu was among China's pioneers in LLM development, founded before OpenAI's transformative release of ChatGPT in late 2022. The ChatGPT launch sparked an AI rush in China, leading to the emergence of numerous companies racing to develop Chinese alternatives. All of Zhipu's major competitors were established in this post-ChatGPT era.
The company's financial prowess is evident in its fundraising history. According to research firm RimeData, Zhipu has completed 14 funding rounds since its inception, raising over 9 billion yuan. Its ability to raise so much money, combined with its early focus on LLMs, has given Zhipu a leg up on its competitors in China's intensely competitive AI landscape.
However, Zhipu's real competition isn't coming from other AI startups, but rather from tech giants like&nbsp;Alibaba,&nbsp;ByteDance, and&nbsp;Tencent, as well as the fast-rising DeepSeek. While Zhipu boasts strong backing from both public and private sources, such established players command even greater financial resources from their highly profitable core businesses.
While AI commercialization remains in its early stages, the race to capture consumer market share reveals the current state of the market. Zhipu's Qingyan consumer app ranks ninth with 9 million monthly active users, significantly behind market leaders. Alibaba's Quark app leads the pack with 149 million monthly active users, followed by ByteDance's Doubao with 107 million and DeepSeek's 96 million, according to April data from AI product tracker Aicpb.com.
That said, consumer applications aren't Zhipu AI's primary focus. The company has positioned itself more strategically as a provider of customized AI solutions for enterprise clients and government organizations, which tend to be more profitable than consumers.
In China's technology market, government organizations, along with national and local state-owned enterprises, are some of the biggest spenders on software and digital solutions – which could work to Zhipu's advantage due to its strong government connections.
But such heavy government reliance carries its own risks. A cautionary tale can be found in the fate of the four "AI dragons" from the pre-ChatGPT era, when AI was primarily associated with recognition technology, in this case involving computer vision.
The four AI dragons –&nbsp;SenseTime&nbsp;(0020.HK),&nbsp;Megvii,&nbsp;CloudWalk&nbsp;(688327.SH) and&nbsp;Yitu&nbsp;–primarily built their businesses on government work, providing surveillance systems powered by computer vision technology. However, these companies have largely faded from prominence following government spending cuts in surveillance-related projects.
Unable to diversify their customer base or expand into new applications, these once-prominent AI companies now find themselves struggling with dwindling business and mounting losses. In a nod to that reality, SenseTime&nbsp;<a href="https://thebambooworks.com/time-for-a-shift-sensetime-formalizes-pivot-to-generative-ai/">has recently been</a>&nbsp;rapidly shifting its business away from its recognition technology roots, and moving towards foundational models with better commercial potential.
At the end of the day, Zhipu's substantial financial resources position it as a likely survivor as it competes against tech giants in China's fast-evolving AI landscape. Still, it faces a critical challenge as it prepares to become first in its class to list: demonstrating to investors it can generate sustainable revenue from its proprietary products and services.

Asia

Equities

IPOs

Opinion

Tech

The Race To Go Public Among New Gen Chinese 'AI Tigers'

D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) with a Buy and maintains $25 price target.

URGN

D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC" or the "Company") today announced that it presented its latest scientific poster, titled "Genetic Toxicity Evaluation of Melatonin in the Bacterial Reverse Mutation Assay," at the <a href="https://pr.report/ab65">2025 Genetic Toxicology Association Annual Meeting</a>, showcasing key non-clinical data that support the genetic safety profile of one of the two active pharmaceutical ingredients ("API") in IGC-AD1, the Company's investigational drug for Alzheimer's disease.
Part of the FDA's battery of safety requirements is to show that APIs are safe for human consumption, including that they do not alter or mutate genes. IGC completed this requirement and is now able to show that the APIs in IGC-AD1 are safe and do not alter genes.

Biotech

General

IGC Pharma Presents Its Latest Scientific Poster, Titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," At The 2025 Genetic Toxicology Association Annual Meeting

Shares of Chinese electric vehicle (EV) maker XPeng Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) surged 7.7% to $21.15 Monday morning following news that the U.S. and China reached a temporary truce in their ongoing trade dispute, agreeing to significantly roll back tariffs on <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">most goods for 90 days</a>.
What To Know: XPeng, an EV manufacturer based in Guangzhou, stands to benefit directly from the <a href="https://www.benzinga.com/topic/tariffs">tariff</a> reduction. The company has been aggressively expanding its footprint in Europe and exploring entry into the North American market.
With tariffs now lowered from 125% to just 10% on most categories, XPeng's cost structure for potential U.S. exports and imported U.S. components likely improves considerably.
Moreover, China's suspension of non-tariff countermeasures, including sanctions and export restrictions on high-tech materials, could ease XPeng's access to advanced semiconductors and batteries, critical to its XNGP autonomous driving platform and upcoming G6 and X9 models.
The easing of geopolitical tensions could also boost investor confidence in XPeng's international strategy and alleviates risks tied to supply chain disruptions and trade barriers.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/05/45327340/3-best-energy-stocks-to-buy-right-now">3 Best Energy Stocks To Buy Right Now</a>
<h2 class="wp-block-heading">How To Buy XPEV Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in XPeng&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XPEV has a 52-week high of $27.16 and a 52-week low of $6.60.

XPEV

XPeng (XPEV) Stock Surges On US–China Tariff Easing: What's Going On?

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.79 percent. This is a 93.08 percent increase over losses of $(10.26) per share from the same period last year.

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

Jianzhi Education Technology Group Company Limited ("Jianzhi") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>), a leading provider of digital educational content in China, today announced it had partnered with China Telecom, one of the world's largest and most influential integrated communications and technology providers. This major collaboration represents a critical step forward in integrating Jianzhi's robust education platforms into China Telecom's expansive cloud center infrastructure.
Following extensive negotiations between the two organizations, this landmark collaboration aims to reshape the future of education by embedding cutting-edge AI-generated content (AIGC) and digital human technologies into every facet of the learning experience.
China Telecom, a Fortune Global 500 company with over 425 million mobile subscribers and operating revenues amounting to US$72.5 billion in 2024, brings immense infrastructure strength, technical support, and national reach to the project. By aligning with&nbsp;Jianzhi, China Telecom will further extend its strategic presence in the digital education space through seamless cloud-based delivery. Jianzhi's cloud-ready educational content and platforms will support the joint development of new cloud-native applications and services tailored to the needs of learners and institutions nationwide.

Jianzhi Education Technology Announces It Had Partnered With China Telecom, Collaboration Aims To Reshape The Future Of Education By Embedding Cutting-Edge AI-Generated Content And Digital Human Technologies Into The Learning Experience

CORRECTION: NRG Energy Q1 Adj. EPS $2.62 Beats $1.49 Estimate, Sales $8.59B Beat $7.83B Estimate

RMTI

Rockwell Medical shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

Reviva Announces Proposed Public Offering

Financing

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

Management

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Health Care

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

Comments

Reviva Pharmaceuticals

Reviva Pharmaceuticals (RVPH) Opciones

Reviva Pharmaceuticals (NASDAQ:RVPH) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL